Xenetic Biosciences, Inc. — Q1 2024 Form 10-Q
Reporting period: Three months ended March 31, 2024. The filing was signed May 9, 2024. Xenetic is a development-stage biopharmaceutical company focused on its DNase immune-oncology platform, while also receiving PolyXen royalties under a Takeda license.
Financial performance
| Metric | Q1 2024 | Q1 2023 | Change |
|---|---|---|---|
| Royalty revenue | $510,817 | $605,844 | Down 15.7% |
| Research and development expense | $944,321 | $595,276 | Up 58.6% |
| General and administrative expense | $834,910 | $925,743 | Down 9.8% |
| Total operating expenses | $1,779,231 | $1,521,019 | Up 17.0% |
| Operating loss | $1,268,414 | $915,175 | Loss increased 38.6% |
| Net loss | $1,195,113 | $856,554 | Loss increased 39.5% |
| Basic and diluted loss per share | $0.78 | $0.56 | — |
| Net cash used in operating activities | $1,159,345 | $1,102,438 | Use increased $56,907 |
The filing does not report a gross margin measure. Royalty revenue declined primarily due to the timing of rebates related to the Takeda sublicense. R&D growth was mainly driven by outside services and contract research organizations supporting preclinical DNase development. Lower accounting and legal fees reduced G&A expense. Higher interest income partly offset operating losses.
Balance sheet and liquidity
- Cash was $7.82 million at March 31, 2024, down from $8.98 million at December 31, 2023. Total assets were $9.39 million; current liabilities were $716,494; and working capital was approximately $7.7 million.
- Total liabilities were $716,494. The balance sheet reports no debt, and the company reported no investing or financing cash flows in the quarter.
- Accumulated deficit was $194.43 million. Cash declined by $1.16 million during the quarter, principally reflecting operating cash use.
Developments, outlook, and risks
- Xenetic is directing internal efforts toward advancing systemic DNase as a potential adjunctive therapy for pancreatic carcinoma and locally advanced or metastatic solid tumors. The program remains in development; no product candidates have regulatory marketing approval.
- Takeda royalties are based on single-digit rates on sales of certain covered products, with revenue recognized upon receipt of Takeda reports. No revenue was reported from the other named research collaborations in the quarter.
- Management expects continuing near-term operating losses. It states existing resources are expected to fund operations for at least 12 months from issuance of the financial statements, but also says recurring losses raise substantial doubt about the company’s ability to continue as a going concern and that additional capital may be needed longer term. Financing availability, timing, and terms are uncertain.
- No specific financial or clinical guidance was provided. Key uncertainties include development and clinical results, access to financing, Nasdaq listing compliance, collaborator and manufacturer performance, and geopolitical and market conditions. The filing reports no material changes to previously disclosed risk factors, no material legal proceedings, and no material contractual-obligation changes.
Investor verification points
- Monitor cash use against management’s stated minimum 12-month funding expectation and assess future financing needs.
- Check subsequent Takeda royalty reports and rebate timing, which affect quarterly revenue.
- Track DNase preclinical milestones, spending, and any transition plans toward clinical development.
- Review the status of collaboration funding and obligations, including the Scripps, UVA, Catalent, and Volition arrangements.
- As of May 3, 2024, 1,540,684 common shares were outstanding; verify dilution and warrant terms, including the approximately 462,963 Series A warrants exercisable at $33 per share and expiring February 23, 2025.